First look: new pill targets 'Undruggable' cancer mutation in chinese patients
NCT ID NCT04380753
Summary
This early-stage study tested a new oral drug called AMG 510 (sotorasib) in 12 patients of Chinese descent with advanced cancers that had a specific genetic change called KRAS G12C. The main goals were to check the drug's safety, how the body processes it, and see if it showed any early signs of shrinking tumors. This was a foundational study to gather initial data in this specific patient population.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS WITH KRAS P.G12C MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
Prince of Wales Hospital
Shatin, New Territories, Hong Kong
-
University of Hong Kong, Queen Mary Hospital
Hong Kong, Hong Kong
-
Veterans General Hospital - Taichung
Taichung, 40705, Taiwan
Conditions
Explore the condition pages connected to this study.